74
Views
3
CrossRef citations to date
0
Altmetric
Editorial

Ezh2, a novel target in detection and therapy of breast cancer

, , &
Pages 2685-2687 | Published online: 22 May 2017

References

  • DeSantisCMaJBryanLJemalABreast cancer statistics. 2013CA Cancer J Clin2014641526224114568
  • MartinsDBecaFSchmittFMetastatic breast cancer: mechanisms and opportunities for cytologyCytopathology201425422523024889678
  • SiegelRNaishadhamDJemalACancer statistics. 2013CA Cancer J Clin2013631113023335087
  • BeaumontTLeadbeaterMTreatment and care of patients with metastatic breast cancerNurs Stand201125404956
  • WangXHuBShenHClinical and prognostic relevance of EZH2 in breast cancer: a meta-analysisBiomed Pharmacother20157521822526271144
  • InariHSuganumaNKawachiKExpression of enhancer of zeste homolog 2 correlates with survival outcome in patients with metastatic breast cancer: exploratory study using primary and paired metastatic lesionsBMC Cancer201717116028241804
  • GuoSLiXRohrJEZH2 overexpression in different immunophenotypes of breast carcinoma and association with clinicopathologic featuresDiagn Pathol2016114127113214
  • JangSHLeeJEOhMHHigh EZH2 protein expression is associated with poor overall survival in patients with luminal a breast cancerJ Breast Cancer2016191536027066096
  • LawrenceCLBaldwinASNon-canonical EZH2 transcriptionally activates RelB in triple negative breast cancerPLoS One20161110e016500527764181
  • KleerCGCaoQVaramballySEZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cellsProc Natl Acad Sci U S A200310020116061161114500907
  • CollettKEideGEArnesJExpression of enhancer of zeste homologue 2 is significantly associated with increased tumor cell proliferation and is a marker of aggressive breast cancerClin Cancer Res20061241168117416489070
  • DingLErdmannCChinnaiyanAMMerajverSDKleerCGIdentification of EZH2 as a molecular marker for a precancerous state in morphologically normal breast tissuesCancer Res20066684095409916618729
  • CaoQYuJDhanasekaranSMRepression of E-cadherin by the polycomb group protein EZH2 in cancerOncogene200827587274728418806826
  • MooreHMGonzalezMEToyKAEZH2 inhibition decreases p38 signaling and suppresses breast cancer motility and metastasisBreast Cancer Res Treat2013138374175223539298
  • ZeidlerMKleerCGThe Polycomb group protein Enhancer of Zeste 2: its links to DNA repair and breast cancerJ Mol Histol2006375–721922316855786
  • AlfordSHToyKMerajverSDKleerCGIncreased risk for distant metastasis in patients with familial early-stage breast cancer and high EZH2 expressionBreast Cancer Res Treat2012132242943721614565
  • MuZLiHFernandezSVAlpaughKRZhangRCristofanilliMEZH2 knockdown suppresses the growth and invasion of human inflammatory breast cancer cellsJ Exp Clin Cancer Res20133217024294976
  • HolmKGrabauDLövgrenKGlobal H3K27 trimethylation and EZH2 abundance in breast tumor subtypesMol Oncol20126549450622766277